Tumour volume reduction after neoadjuvant chemotherapy impacts outcome in localised embryonal rhabdomyosarcoma
Background Response (tumour volume reduction) to induction chemotherapy has been used to stratify secondary local and systemic treatment of Intergroup Rhabdomyosarcoma Study Group III (IRSG‐III) embryonal rhabdomyosarcoma (RME) in consecutive CWS‐trials. To evaluate its actual impact we studied resp...
Saved in:
| Published in: | Pediatric blood & cancer Vol. 62; no. 1; pp. 16 - 23 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Blackwell Publishing Ltd
01-01-2015
Wiley Subscription Services, Inc |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background
Response (tumour volume reduction) to induction chemotherapy has been used to stratify secondary local and systemic treatment of Intergroup Rhabdomyosarcoma Study Group III (IRSG‐III) embryonal rhabdomyosarcoma (RME) in consecutive CWS‐trials. To evaluate its actual impact we studied response‐related treatment and outcomes.
Procedure
Patients with IRSG‐III RME <21 years and non‐response (NR, <33% volume reduction) in five consecutive CWS‐trials were analysed and compared with partial responders (PAR, ≥33% reduction). The NR was reviewed and sub‐classified as Objective Response (OR, <0%–33% reduction) or Stable/Progressive Disease (SPD).
Results
Fifty‐nine of 529 patients had NR (n = 34 OR, n = 25 SPD). Primary risk‐factors including age, tumour size, and TN‐classification did not differ between NR and PAR groups but NR had more patients with unfavourable sites comparatively (P = 0.04). There were no differences in primary risk‐factors between OR and SPD. Significant factors associated with poor outcome in multivariate analysis were NR, TN‐classification, age >10 years, tumour size >5 cm and therapy in older trials. After response assessment n = 24 NR continued to receive induction chemotherapy, n = 32 received other combinations and n = 3 no further chemotherapy. Forty‐two non‐responders were irradiated, and the tumours were completely resected in n = 20. After a median follow‐up of 8 years, 34 NR are alive. Seventeen of 21 failures leading to disease‐related deaths were locoregional. The five‐year overall survival rate (OS) was 76 ± 4% for PAR, 79 ± 14% for OR, but only 40 ± 19% for SPD (P < 0.001).
Conclusion
Response to induction chemotherapy appears to be an important surrogate marker of poor outcome in patients with SPD largely due to ineffective local control. Pediatr Blood Cancer 2015;62:16–23. © 2014 Wiley Periodicals, Inc. |
|---|---|
| AbstractList | Response (tumour volume reduction) to induction chemotherapy has been used to stratify secondary local and systemic treatment of Intergroup Rhabdomyosarcoma Study Group III (IRSG-III) embryonal rhabdomyosarcoma (RME) in consecutive CWS-trials. To evaluate its actual impact we studied response-related treatment and outcomes.
Patients with IRSG-III RME <21 years and non-response (NR, <33% volume reduction) in five consecutive CWS-trials were analysed and compared with partial responders (PAR, ≥ 33% reduction). The NR was reviewed and sub-classified as Objective Response (OR, <0%-33% reduction) or Stable/Progressive Disease (SPD).
Fifty-nine of 529 patients had NR (n = 34 OR, n = 25 SPD). Primary risk-factors including age, tumour size, and TN-classification did not differ between NR and PAR groups but NR had more patients with unfavourable sites comparatively (P = 0.04). There were no differences in primary risk-factors between OR and SPD. Significant factors associated with poor outcome in multivariate analysis were NR, TN-classification, age >10 years, tumour size >5 cm and therapy in older trials. After response assessment n = 24 NR continued to receive induction chemotherapy, n = 32 received other combinations and n = 3 no further chemotherapy. Forty-two non-responders were irradiated, and the tumours were completely resected in n = 20. After a median follow-up of 8 years, 34 NR are alive. Seventeen of 21 failures leading to disease-related deaths were locoregional. The five-year overall survival rate (OS) was 76 ± 4% for PAR, 79 ± 14% for OR, but only 40 ± 19% for SPD (P < 0.001).
Response to induction chemotherapy appears to be an important surrogate marker of poor outcome in patients with SPD largely due to ineffective local control. Background Response (tumour volume reduction) to induction chemotherapy has been used to stratify secondary local and systemic treatment of Intergroup Rhabdomyosarcoma Study Group III (IRSG-III) embryonal rhabdomyosarcoma (RME) in consecutive CWS-trials. To evaluate its actual impact we studied response-related treatment and outcomes. Procedure Patients with IRSG-III RME <21 years and non-response (NR, <33% volume reduction) in five consecutive CWS-trials were analysed and compared with partial responders (PAR, ≥33% reduction). The NR was reviewed and sub-classified as Objective Response (OR, <0%-33% reduction) or Stable/Progressive Disease (SPD). Results Fifty-nine of 529 patients had NR (n=34 OR, n=25 SPD). Primary risk-factors including age, tumour size, and TN-classification did not differ between NR and PAR groups but NR had more patients with unfavourable sites comparatively (P=0.04). There were no differences in primary risk-factors between OR and SPD. Significant factors associated with poor outcome in multivariate analysis were NR, TN-classification, age >10 years, tumour size >5cm and therapy in older trials. After response assessment n=24 NR continued to receive induction chemotherapy, n=32 received other combinations and n=3 no further chemotherapy. Forty-two non-responders were irradiated, and the tumours were completely resected in n=20. After a median follow-up of 8 years, 34 NR are alive. Seventeen of 21 failures leading to disease-related deaths were locoregional. The five-year overall survival rate (OS) was 76±4% for PAR, 79±14% for OR, but only 40±19% for SPD (P<0.001). Conclusion Response to induction chemotherapy appears to be an important surrogate marker of poor outcome in patients with SPD largely due to ineffective local control. Pediatr Blood Cancer 2015;62:16-23. © 2014 Wiley Periodicals, Inc. BACKGROUNDResponse (tumour volume reduction) to induction chemotherapy has been used to stratify secondary local and systemic treatment of Intergroup Rhabdomyosarcoma Study Group III (IRSG-III) embryonal rhabdomyosarcoma (RME) in consecutive CWS-trials. To evaluate its actual impact we studied response-related treatment and outcomes.PROCEDUREPatients with IRSG-III RME <21 years and non-response (NR, <33% volume reduction) in five consecutive CWS-trials were analysed and compared with partial responders (PAR, ≥ 33% reduction). The NR was reviewed and sub-classified as Objective Response (OR, <0%-33% reduction) or Stable/Progressive Disease (SPD).RESULTSFifty-nine of 529 patients had NR (n = 34 OR, n = 25 SPD). Primary risk-factors including age, tumour size, and TN-classification did not differ between NR and PAR groups but NR had more patients with unfavourable sites comparatively (P = 0.04). There were no differences in primary risk-factors between OR and SPD. Significant factors associated with poor outcome in multivariate analysis were NR, TN-classification, age >10 years, tumour size >5 cm and therapy in older trials. After response assessment n = 24 NR continued to receive induction chemotherapy, n = 32 received other combinations and n = 3 no further chemotherapy. Forty-two non-responders were irradiated, and the tumours were completely resected in n = 20. After a median follow-up of 8 years, 34 NR are alive. Seventeen of 21 failures leading to disease-related deaths were locoregional. The five-year overall survival rate (OS) was 76 ± 4% for PAR, 79 ± 14% for OR, but only 40 ± 19% for SPD (P < 0.001).CONCLUSIONResponse to induction chemotherapy appears to be an important surrogate marker of poor outcome in patients with SPD largely due to ineffective local control. Background Response (tumour volume reduction) to induction chemotherapy has been used to stratify secondary local and systemic treatment of Intergroup Rhabdomyosarcoma Study Group III (IRSG‐III) embryonal rhabdomyosarcoma (RME) in consecutive CWS‐trials. To evaluate its actual impact we studied response‐related treatment and outcomes. Procedure Patients with IRSG‐III RME <21 years and non‐response (NR, <33% volume reduction) in five consecutive CWS‐trials were analysed and compared with partial responders (PAR, ≥33% reduction). The NR was reviewed and sub‐classified as Objective Response (OR, <0%–33% reduction) or Stable/Progressive Disease (SPD). Results Fifty‐nine of 529 patients had NR (n = 34 OR, n = 25 SPD). Primary risk‐factors including age, tumour size, and TN‐classification did not differ between NR and PAR groups but NR had more patients with unfavourable sites comparatively ( P = 0.04). There were no differences in primary risk‐factors between OR and SPD. Significant factors associated with poor outcome in multivariate analysis were NR, TN‐classification, age >10 years, tumour size >5 cm and therapy in older trials. After response assessment n = 24 NR continued to receive induction chemotherapy, n = 32 received other combinations and n = 3 no further chemotherapy. Forty‐two non‐responders were irradiated, and the tumours were completely resected in n = 20. After a median follow‐up of 8 years, 34 NR are alive. Seventeen of 21 failures leading to disease‐related deaths were locoregional. The five‐year overall survival rate (OS) was 76 ± 4% for PAR, 79 ± 14% for OR, but only 40 ± 19% for SPD ( P < 0.001). Conclusion Response to induction chemotherapy appears to be an important surrogate marker of poor outcome in patients with SPD largely due to ineffective local control. Pediatr Blood Cancer 2015;62:16–23. © 2014 Wiley Periodicals, Inc. Background Response (tumour volume reduction) to induction chemotherapy has been used to stratify secondary local and systemic treatment of Intergroup Rhabdomyosarcoma Study Group III (IRSG‐III) embryonal rhabdomyosarcoma (RME) in consecutive CWS‐trials. To evaluate its actual impact we studied response‐related treatment and outcomes. Procedure Patients with IRSG‐III RME <21 years and non‐response (NR, <33% volume reduction) in five consecutive CWS‐trials were analysed and compared with partial responders (PAR, ≥33% reduction). The NR was reviewed and sub‐classified as Objective Response (OR, <0%–33% reduction) or Stable/Progressive Disease (SPD). Results Fifty‐nine of 529 patients had NR (n = 34 OR, n = 25 SPD). Primary risk‐factors including age, tumour size, and TN‐classification did not differ between NR and PAR groups but NR had more patients with unfavourable sites comparatively (P = 0.04). There were no differences in primary risk‐factors between OR and SPD. Significant factors associated with poor outcome in multivariate analysis were NR, TN‐classification, age >10 years, tumour size >5 cm and therapy in older trials. After response assessment n = 24 NR continued to receive induction chemotherapy, n = 32 received other combinations and n = 3 no further chemotherapy. Forty‐two non‐responders were irradiated, and the tumours were completely resected in n = 20. After a median follow‐up of 8 years, 34 NR are alive. Seventeen of 21 failures leading to disease‐related deaths were locoregional. The five‐year overall survival rate (OS) was 76 ± 4% for PAR, 79 ± 14% for OR, but only 40 ± 19% for SPD (P < 0.001). Conclusion Response to induction chemotherapy appears to be an important surrogate marker of poor outcome in patients with SPD largely due to ineffective local control. Pediatr Blood Cancer 2015;62:16–23. © 2014 Wiley Periodicals, Inc. BACKGROUND: Response (tumour volume reduction) to induction chemotherapy has been used to stratify secondary local and systemic treatment of Intergroup Rhabdomyosarcoma Study Group III (IRSG-III) embryonal rhabdomyosarcoma (RME) in consecutive CWS-trials. To evaluate its actual impact we studied response-related treatment and outcomes. PROCEDURE: Patients with IRSG-III RME <21 years and non-response (NR, <33% volume reduction) in five consecutive CWS-trials were analysed and compared with partial responders (PAR, ≥33% reduction). The NR was reviewed and sub-classified as Objective Response (OR, <0%-33% reduction) or Stable/Progressive Disease (SPD). RESULTS: Fifty-nine of 529 patients had NR (n = 34 OR, n = 25 SPD). Primary risk-factors including age, tumour size, and TN-classification did not differ between NR and PAR groups but NR had more patients with unfavourable sites comparatively (P = 0.04). There were no differences in primary risk-factors between OR and SPD. Significant factors associated with poor outcome in multivariate analysis were NR, TN-classification, age >10 years, tumour size >5 cm and therapy in older trials. After response assessment n = 24 NR continued to receive induction chemotherapy, n = 32 received other combinations and n = 3 no further chemotherapy. Forty-two non-responders were irradiated, and the tumours were completely resected in n = 20. After a median follow-up of 8 years, 34 NR are alive. Seventeen of 21 failures leading to disease-related deaths were locoregional. The five-year overall survival rate (OS) was 76 ± 4% for PAR, 79 ± 14% for OR, but only 40 ± 19% for SPD (P < 0.001). CONCLUSION: Response to induction chemotherapy appears to be an important surrogate marker of poor outcome in patients with SPD largely due to ineffective local control. |
| Author | Stark, Monika Fuchs, Jörg Feuchtgruber, Simone Bielack, Stefan S. Linderkamp, Christin Ljungman, Gustaf Hagen, Rudolf Selle, Barbara Handgretinger, Rupert Koscielniak, Ewa Kazanowska, Bernarda Timmermann, Beate Kube, Stefanie Ladenstein, Ruth Kosztyla, Daniel Niggli, Felix Dantonello, Tobias M. Klingebiel, Thomas |
| Author_xml | – sequence: 1 givenname: Tobias M. surname: Dantonello fullname: Dantonello, Tobias M. email: Correspondence to: Tobias M. Dantonello, Olgahospital, Paediatrics 5 (oncology, hematology, immunology), Klinikum Stuttgart, Kriegsbergstrasse 62, D-70174 Stuttgart, Germany. or, tobias.dantonello@olgahospital-stuttgart.det.dantonello@klinikum-stuttgart.de organization: Paediatrics 5 (oncology, hematology, immunology), Olgahospital, Klinikum Stuttgart, Stuttgart, Germany – sequence: 2 givenname: Monika surname: Stark fullname: Stark, Monika organization: Paediatrics 5 (oncology, hematology, immunology), Olgahospital, Klinikum Stuttgart, Stuttgart, Germany – sequence: 3 givenname: Beate surname: Timmermann fullname: Timmermann, Beate organization: Westdeutsches Protonentherapiezentrum, University of Essen, Essen, Germany – sequence: 4 givenname: Jörg surname: Fuchs fullname: Fuchs, Jörg organization: Department for Paediatric Surgery and Paediatric Urology, University of Tuebingen, Tuebingen, Germany – sequence: 5 givenname: Barbara surname: Selle fullname: Selle, Barbara organization: Department of Paediatric Oncology, Helios Klinikum, Berlin-BuchBerlin, Germany – sequence: 6 givenname: Christin surname: Linderkamp fullname: Linderkamp, Christin organization: Department of Paediatric Oncology, University of Hannover, Hannover, Germany – sequence: 7 givenname: Rupert surname: Handgretinger fullname: Handgretinger, Rupert organization: Department of Paediatric Oncology, University of Tuebingen, Tuebingen, Germany – sequence: 8 givenname: Rudolf surname: Hagen fullname: Hagen, Rudolf organization: Department of Ear, Nose and Throat Surgery, University of Wuerzburg, Wuerzburg, Germany – sequence: 9 givenname: Simone surname: Feuchtgruber fullname: Feuchtgruber, Simone organization: Paediatrics 5 (oncology, hematology, immunology), Olgahospital, Klinikum Stuttgart, Stuttgart, Germany – sequence: 10 givenname: Stefanie surname: Kube fullname: Kube, Stefanie organization: Paediatrics 5 (oncology, hematology, immunology), Olgahospital, Klinikum Stuttgart, Stuttgart, Germany – sequence: 11 givenname: Daniel surname: Kosztyla fullname: Kosztyla, Daniel organization: Paediatrics 5 (oncology, hematology, immunology), Olgahospital, Klinikum Stuttgart, Stuttgart, Germany – sequence: 12 givenname: Bernarda surname: Kazanowska fullname: Kazanowska, Bernarda organization: Department of Paediatric Oncology, University of Wroclaw, Wroclaw, Poland – sequence: 13 givenname: Ruth surname: Ladenstein fullname: Ladenstein, Ruth organization: St. Anna Kinderspital, Vienna, Austria – sequence: 14 givenname: Felix surname: Niggli fullname: Niggli, Felix organization: Department of Paediatric Oncology, University of Zuerich, Zuerich, Switzerland – sequence: 15 givenname: Gustaf surname: Ljungman fullname: Ljungman, Gustaf organization: Department of Women's and Children's Health, University of Uppsala, Uppsala, Sweden – sequence: 16 givenname: Stefan S. surname: Bielack fullname: Bielack, Stefan S. organization: Paediatrics 5 (oncology, hematology, immunology), Olgahospital, Klinikum Stuttgart, Stuttgart, Germany – sequence: 17 givenname: Thomas surname: Klingebiel fullname: Klingebiel, Thomas organization: Department of Paediatric Oncology, University of Frankfurt, Frankfurt (Main), Germany – sequence: 18 givenname: Ewa surname: Koscielniak fullname: Koscielniak, Ewa organization: Paediatrics 5 (oncology, hematology, immunology), Olgahospital, Klinikum Stuttgart, Stuttgart, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25263634$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-240257$$DView record from Swedish Publication Index |
| BookMark | eNp10ctu1TAQBuAIFdELLHgBZIkNSKR1HF-SZXuAFqkCKpW2O8txxhwfkjjYcUveHrdpzwIJeWEvvhl55t_PdgY3QJa9LvBhgTE5Ght9SBjB4lm2VzDKcoYLsbN943o32w9hkyjHrHqR7SbMS17SvWy4jL2LHt26LvaAPLRRT9YNSJkJPBrAqXYTb9UwIb2G3k1r8Gqcke1HpaeAXJy0S4V2QJ3TqrMBWgR942c3qA75tWpa188uKJ-cepk9N6oL8OrxPsh-fP50uTrLz7-dflkdn-eakkrkGhvMy6ZqKQXT0lJTXhGhG2M41bikRnAuKmKYagQ2rC21MXVNOBRQK66K8iD7sPQNdzDGRo7e9srP0ikrP9qrY-n8TxmjJBQTJhJ_t_DRu98RwiR7GzR0nUoLiEEWnAicDr-nb_-hm7S_NOuDYrwglNVJvV-U9i4ED2b7gwLL-8xkykw-ZJbsm8eOsemh3cqnkBI4WsCd7WD-fyf5_WT11DJfKmyY4M-2QvlfMo0gmLz-eirPbi5uruurC1mVfwFImLOu |
| CitedBy_id | crossref_primary_10_3389_fped_2021_783754 crossref_primary_10_3390_cancers14040899 crossref_primary_10_1016_S1470_2045_18_30337_1 crossref_primary_10_1002_alr_23262 crossref_primary_10_1007_s00247_021_05081_0 crossref_primary_10_1053_j_sempedsurg_2016_09_011 crossref_primary_10_1002_cam4_1940 crossref_primary_10_1038_s41598_023_36568_5 crossref_primary_10_1053_j_semnuclmed_2024_01_005 crossref_primary_10_3390_medicina56070362 crossref_primary_10_1007_s00247_023_05596_8 crossref_primary_10_1016_j_acthis_2016_02_004 crossref_primary_10_1016_j_ejrad_2023_111012 crossref_primary_10_1016_j_ijrobp_2015_01_049 crossref_primary_10_3390_cancers12123808 crossref_primary_10_3390_cancers13030510 crossref_primary_10_1007_s00428_018_2311_7 crossref_primary_10_1002_cncr_31157 crossref_primary_10_1002_pbc_26510 crossref_primary_10_5409_wjcp_v4_i4_94 crossref_primary_10_3390_cancers14092270 |
| Cites_doi | 10.1080/01621459.1958.10501452 10.1016/S1470-2045(05)01733-X 10.1200/JCO.2002.20.3.776 10.1200/JCO.2006.10.4257 10.1200/JCO.2009.22.3768 10.1016/j.ejca.2013.11.031 10.1016/j.ijrobp.2006.08.053 10.1016/j.ejca.2007.01.033 10.1182/blood-2009-10-248146 10.1016/j.ejca.2007.11.013 10.1007/978-1-4419-0284-9_18 10.1016/S0360-3016(01)01709-6 10.1200/JCO.2010.29.0247 10.1007/s00508-004-5-0285-8 10.1200/JCO.1999.17.12.3736 10.3109/02841868909111184 10.1200/JCO.2007.12.2382 10.1200/JCO.2008.19.5933 10.1002/cncr.27775 10.1056/NEJMoa1110169 10.1200/JCO.2012.42.4275 10.1200/JCO.2005.11.909 10.1002/1097-0142(19921115)70:10<2557::AID-CNCR2820701027>3.0.CO;2-8 10.1056/NEJMsa060185 10.1016/S0959-8049(98)00024-0 10.1002/(SICI)1097-0142(19971101)80:9<1717::AID-CNCR4>3.0.CO;2-B 10.1200/JCO.2007.15.0466 10.1002/pbc.24598 10.1002/pbc.22950 10.1002/cncr.10669 10.1200/JCO.1999.17.12.3706 10.1200/JCO.1988.6.2.308 10.1002/1097-0142(197412)34:6<2128::AID-CNCR2820340638>3.0.CO;2-M 10.1200/JCO.2009.25.0803 10.1200/JCO.2001.19.12.3091 10.1001/jama.290.12.1583 10.1002/cncr.27934 |
| ContentType | Journal Article |
| Copyright | 2014 Wiley Periodicals, Inc. |
| Copyright_xml | – notice: 2014 Wiley Periodicals, Inc. |
| CorporateAuthor | Cooperative Weichteilsarkom Studiengruppe [CWS] on behalf of the Cooperative Weichteilsarkom Studiengruppe [CWS] |
| CorporateAuthor_xml | – name: Cooperative Weichteilsarkom Studiengruppe [CWS] – name: on behalf of the Cooperative Weichteilsarkom Studiengruppe [CWS] |
| DBID | BSCLL CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T5 7TK 7TO 8FD FR3 H94 K9. P64 RC3 7X8 ADTPV AOWAS DF2 |
| DOI | 10.1002/pbc.25207 |
| DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Immunology Abstracts Neurosciences Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic SwePub SwePub Articles SWEPUB Uppsala universitet |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Genetics Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Genetics Abstracts MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1545-5017 |
| EndPage | 23 |
| ExternalDocumentID | oai_DiVA_org_uu_240257 3499428581 10_1002_pbc_25207 25263634 PBC25207 ark_67375_WNG_HXQXW9VQ_8 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: German Childhood Cancer Foundation, Bonn – fundername: German Cancer Aid, Bonn – fundername: Förderkreis Krebskranke Kinder e.V. Stuttgart, Germany |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 123 1L6 1OC 31~ 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAWTL AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ABPPZ ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SUPJJ SV3 TEORI UB1 UDS V2E W8V W99 WBKPD WHWMO WIH WIJ WIK WJL WOHZO WQJ WRC WVDHM WXI WXSBR XG1 XV2 ~IA ~WT CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T5 7TK 7TO 8FD FR3 H94 K9. P64 RC3 7X8 ADTPV AOWAS DF2 |
| ID | FETCH-LOGICAL-c4287-c0f063b8d44efd43c46827cbff64c034f766782f5ab70f5d3cff9926e1e9a6a13 |
| IEDL.DBID | 33P |
| ISSN | 1545-5009 1545-5017 |
| IngestDate | Sat Aug 24 00:16:33 EDT 2024 Sat Aug 17 04:02:48 EDT 2024 Thu Oct 10 17:50:33 EDT 2024 Fri Aug 23 03:28:58 EDT 2024 Sat Sep 28 07:55:47 EDT 2024 Sat Aug 24 00:53:42 EDT 2024 Wed Oct 30 09:54:10 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | chemotherapy embryonal rhabdomyosarcoma response |
| Language | English |
| License | 2014 Wiley Periodicals, Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4287-c0f063b8d44efd43c46827cbff64c034f766782f5ab70f5d3cff9926e1e9a6a13 |
| Notes | ark:/67375/WNG-HXQXW9VQ-8 Förderkreis Krebskranke Kinder e.V. Stuttgart, Germany German Childhood Cancer Foundation, Bonn German Cancer Aid, Bonn istex:4A640F8088A69D1BD9D3991C70C5B2DC0B3476A2 ArticleID:PBC25207 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 25263634 |
| PQID | 1625612459 |
| PQPubID | 1036357 |
| PageCount | 8 |
| ParticipantIDs | swepub_primary_oai_DiVA_org_uu_240257 proquest_miscellaneous_1627070767 proquest_journals_1625612459 crossref_primary_10_1002_pbc_25207 pubmed_primary_25263634 wiley_primary_10_1002_pbc_25207_PBC25207 istex_primary_ark_67375_WNG_HXQXW9VQ_8 |
| PublicationCentury | 2000 |
| PublicationDate | 2015-01 January 2015 2015-Jan 2015-01-00 20150101 2015 |
| PublicationDateYYYYMMDD | 2015-01-01 |
| PublicationDate_xml | – month: 01 year: 2015 text: 2015-01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Glenview |
| PublicationTitle | Pediatric blood & cancer |
| PublicationTitleAlternate | Pediatr Blood Cancer |
| PublicationYear | 2015 |
| Publisher | Blackwell Publishing Ltd Wiley Subscription Services, Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley Subscription Services, Inc |
| References | Koscielniak E, Kosztyla D, Dantonello T, et al. Report of the CWS-2002 -P study: Treatment results for soft tissue sarcomas (STS) in childhood and adolescence. Pediatr Blood Cancer 2013; 60:32. Modritz D, Ladenstein R, Potschger U, et al. Treatment for soft tissue sarcoma in childhood and adolescence. Austrian results within the CWS 96 study. Wien Klin Wochenschr 2005; 117:196-209. Burke M, Anderson JR, Kao SC, et al. Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: The intergroup rhabdomyosarcoma study-IV experience-a report from the soft tissue sarcoma committee of the children's oncology group. J Clin Oncol 2007; 25:4909-4913. Treuner J, Suder J, Keim M, et al. The predictive value of initial cytostatic response in primary unresectable rhabdomyosarcoma in children. Acta Oncol 1989; 28:67-72. Ferrari A, Miceli R, Meazza C, et al. Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma. J Clin Oncol 2010; 28:1322-1328. Donaldson SS, Meza J, Breneman JC, et al. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma-a report from the IRSG. Int J Radiat Oncol Biol Phys 2001; 51:718-728. Rosenberg AR, Anderson JR, Lyden E, et al. Early response as assessed by anatomic imaging does not predict failure-free survival among patients with group III rhabdomyosarcoma: A report from the Children's Oncology Group. Eur J Cancer 2014; 50:816-823. Schrappe M, Hunger SP, Pui CH, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 2012; 366:1371-1381. Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's oncology group study D 980. J Clin Oncol 2009; 27:5182-5188. Dantonello TM, Int-Veen C, Winkler P, et al. Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. J Clin Oncol 2008; 26:406-413. Horowitz ME, Etcubanas E, Christensen ML, et al. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: A model for anticancer drug development. J Clin Oncol 1988; 6:308-314. Little DJ, Ballo MT, Zagars GK, et al. Adult rhabdomyosarcoma: Outcome following multimodality treatment. Cancer 2002; 95:377-388. Marina N, Bielack S, Whelan J, et al. International collaboration is feasible in trials for rare conditions: The EURAMOS experience. Cancer Treat Res 2009; 152:339-353. Douglas JG, Arndt CA, Hawkins DS. Delayed radiotherapy following dose intensive chemotherapy for parameningeal rhabdomyosarcoma (PM-RMS) of childhood. Eur J Cancer 2007; 43:1045-1050. Kaplan EL, Meyer P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481. Heyn RM, Holland R, Newton WA Jr, et al. The role of combined chemotherapy in the treatment of rhabdomyosarcoma in children. Cancer 1974; 34:2128-2142. Meyer WH. Playing bad cards properly: Challenges to improving cure rates in rhabdomyosarcoma. J Clin Oncol 2012; 30:2431-2433. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355:1572-1582. Seitz G, Dantonello TM, Int-Veen C, et al. Treatment efficiency, outcome and surgical treatment problems in patients suffering from localized embryonal bladder/prostate rhabdomyosarcoma: A report from the cooperative soft tissue sarcoma trial CWS-96. Pediatr Blood Cancer 2011; 56:718-724. Timmermann B, Schuck A, Niggli F, et al. Spot-scanning proton therapy for malignant soft tissue tumors in childhood: First experiences at the Paul Scherrer Institute. Int J Radiat Oncol Biol Phys 2007; 67:497-504. Raney RB Jr, Gehan EA, Maurer HM, et al. Evaluation of intensified chemotherapy in children with advanced rhabdomyosarcoma (clinical groups III and IV). The Intergroup Rhabdomyosarcoma Study (IRS) committee of the cancer and leukemia group B children's cancer study group, Southwest oncology group. Cancer Clin Trials 1979; 2:19-28. Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult long-term survivors of childhood cancer: A report from the childhood cancer survivor Study. Jama 2003; 290:1583-1592. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: Results for patients with nonmetastatic disease. J Clin Oncol 2001; 19:3091-3102. Donaldson SS, Anderson JR. Rhabdomyosarcoma: Many similarities, a few philosophical differences. J Clin Oncol 2005; 23:2586-2587. Rodeberg DA, Stoner JA, Hayes-Jordan A, et al. Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: A report from the children's oncology group. J Clin Oncol 2009; 27:3705-3711. Gaynon PS, Desai AA, Bostrom BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: A review. Cancer 1997; 80:1717-1726. Koscielniak E, Jurgens H, Winkler K, et al. Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German cooperative soft yissue sarcoma study. Cancer 1992; 70:2557-2567. Weihkopf T, Blettner M, Dantonello T, et al. Incidence and time trends of soft tissue sarcomas in German children 1985-2004-a report from the population-based German childhood cancer registry. Eur J Cancer 2008; 44:432-440. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115:3206-3214. Schellong G, Potter R, Bramswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999; 17:3736-3744. Yoo SY, Kim JS, Sung KW, et al. The degree of tumor volume reduction during the early phase of induction chemotherapy is an independent prognostic factor in patients with high-risk neuroblastoma. Cancer 2013; 119:656-664. Mattke A, Kunz D, Knietig R, et al. Response rate and prognosis depending on response in rhabdomyosarcoma. A report from the CWS Study. Pediatr Blood Cancer 2001; 37. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1, 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20:776-790. Minn AY, Lyden ER, Anderson JR, et al. Early treatment failure in intermediate-risk rhabdomyosarcoma: results from IRS-IV and D 9803-a report from the children's oncology group. J Clin Oncol 2010; 28:4228-4232. Koscielniak E, Harms D, Henze G, et al. Results of treatment for soft tissue sarcoma in childhood and adolescence: A final report of the German cooperative soft tissue sarcoma study CWS-86. J Clin Oncol 1999; 17:3706-3719. Eaton BR, McDonald MW, Kim S, et al. Radiation therapy target volume reduction in pediatric rhabdomyosarcoma: Implications for patterns of disease recurrence and overall survival. Cancer 2013; 119:1578-1585. Rossig C, Juergens H, Schrappe M, et al. Effective childhood cancer treatment: The impact of large scale clinical trials in Germany and Austria. Pediatr Blood Cancer 2013; 60:1574-1581. Flamant F, Rodary C, Rey A, et al. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the international society of paediatric oncology: MMT84. Eur J Cancer 1998; 34:1050-1062. Stevens MC. Treatment for childhood rhabdomyosarcoma: The cost of cure. Lancet Oncol 2005; 6:77-84. Dantonello TM, Int-Veen C, Harms D, et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol 2009; 27:1446-1455. Greenwood M. Reports on public health and medical subjects the errors of sampling of the survivorship tables. London: HM Stationery Office; 1926. 1997; 80 1974; 34 2012; 366 2010 2002; 95 2005; 117 1958; 53 2003; 290 2011; 56 2009; 152 2009; 27 2005; 23 1989; 28 2012; 30 2006; 355 1992; 70 2013; 119 2002; 20 2010; 28 1999; 17 1988; 6 2010; 115 2001; 19 2008; 26 2013; 60 2005; 6 1979; 2 2001; 37 2008; 44 2007; 43 2014; 50 1926 2007; 67 1998; 34 2001; 51 2007; 25 Greenwood M (e_1_2_6_22_1) 1926 e_1_2_6_32_1 e_1_2_6_10_1 e_1_2_6_31_1 e_1_2_6_30_1 e_1_2_6_19_1 e_1_2_6_13_1 e_1_2_6_36_1 e_1_2_6_14_1 e_1_2_6_35_1 e_1_2_6_11_1 Koscielniak E (e_1_2_6_20_1) 2013; 60 e_1_2_6_12_1 e_1_2_6_33_1 e_1_2_6_17_1 e_1_2_6_18_1 e_1_2_6_39_1 e_1_2_6_15_1 e_1_2_6_38_1 e_1_2_6_16_1 Raney RB (e_1_2_6_37_1) 1979; 2 Widemann BC (e_1_2_6_34_1) 2010 e_1_2_6_43_1 e_1_2_6_21_1 e_1_2_6_41_1 e_1_2_6_40_1 e_1_2_6_9_1 e_1_2_6_8_1 e_1_2_6_5_1 e_1_2_6_4_1 e_1_2_6_7_1 e_1_2_6_6_1 e_1_2_6_25_1 e_1_2_6_24_1 e_1_2_6_3_1 e_1_2_6_23_1 e_1_2_6_2_1 e_1_2_6_29_1 Mattke A (e_1_2_6_42_1) 2001; 37 e_1_2_6_28_1 e_1_2_6_27_1 e_1_2_6_26_1 |
| References_xml | – volume: 70 start-page: 2557 year: 1992 end-page: 2567 article-title: Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German cooperative soft yissue sarcoma study publication-title: Cancer – volume: 290 start-page: 1583 year: 2003 end-page: 1592 article-title: Health status of adult long‐term survivors of childhood cancer: A report from the childhood cancer survivor Study publication-title: Jama – volume: 117 start-page: 196 year: 2005 end-page: 209 article-title: Treatment for soft tissue sarcoma in childhood and adolescence. Austrian results within the CWS 96 study publication-title: Wien Klin Wochenschr – volume: 80 start-page: 1717 year: 1997 end-page: 1726 article-title: Early response to therapy and outcome in childhood acute lymphoblastic leukemia: A review publication-title: Cancer – volume: 44 start-page: 432 year: 2008 end-page: 440 article-title: Incidence and time trends of soft tissue sarcomas in German children 1985–2004—a report from the population‐based German childhood cancer registry publication-title: Eur J Cancer – volume: 34 start-page: 1050 year: 1998 end-page: 1062 article-title: Treatment of non‐metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the international society of paediatric oncology: MMT84 publication-title: Eur J Cancer – volume: 17 start-page: 3706 year: 1999 end-page: 3719 article-title: Results of treatment for soft tissue sarcoma in childhood and adolescence: A final report of the German cooperative soft tissue sarcoma study CWS‐86 publication-title: J Clin Oncol – volume: 6 start-page: 308 year: 1988 end-page: 314 article-title: Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: A model for anticancer drug development publication-title: J Clin Oncol – volume: 43 start-page: 1045 year: 2007 end-page: 1050 article-title: Delayed radiotherapy following dose intensive chemotherapy for parameningeal rhabdomyosarcoma (PM‐RMS) of childhood publication-title: Eur J Cancer – volume: 152 start-page: 339 year: 2009 end-page: 353 article-title: International collaboration is feasible in trials for rare conditions: The EURAMOS experience publication-title: Cancer Treat Res – volume: 60 start-page: 32 year: 2013 article-title: Report of the CWS‐2002 ‐P study: Treatment results for soft tissue sarcomas (STS) in childhood and adolescence publication-title: Pediatr Blood Cancer – volume: 51 start-page: 718 year: 2001 end-page: 728 article-title: Results from the IRS‐IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma—a report from the IRSG publication-title: Int J Radiat Oncol Biol Phys – volume: 53 start-page: 457 year: 1958 end-page: 481 article-title: Non‐parametric estimation from incomplete observations publication-title: J Am Stat Assoc – volume: 34 start-page: 2128 year: 1974 end-page: 2142 article-title: The role of combined chemotherapy in the treatment of rhabdomyosarcoma in children publication-title: Cancer – volume: 23 start-page: 2586 year: 2005 end-page: 2587 article-title: Rhabdomyosarcoma: Many similarities, a few philosophical differences publication-title: J Clin Oncol – volume: 25 start-page: 4909 year: 2007 end-page: 4913 article-title: Assessment of response to induction therapy and its influence on 5‐year failure‐free survival in group III rhabdomyosarcoma: The intergroup rhabdomyosarcoma study‐IV experience–a report from the soft tissue sarcoma committee of the children's oncology group publication-title: J Clin Oncol – volume: 6 start-page: 77 year: 2005 end-page: 84 article-title: Treatment for childhood rhabdomyosarcoma: The cost of cure publication-title: Lancet Oncol – volume: 26 start-page: 406 year: 2008 end-page: 413 article-title: Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma publication-title: J Clin Oncol – volume: 28 start-page: 1322 year: 2010 end-page: 1328 article-title: Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma publication-title: J Clin Oncol – volume: 17 start-page: 3736 year: 1999 end-page: 3744 article-title: High cure rates and reduced long‐term toxicity in pediatric Hodgkin's disease: the German‐Austrian multicenter trial DAL‐HD‐90. The German‐Austrian Pediatric Hodgkin's Disease Study Group publication-title: J Clin Oncol – volume: 19 start-page: 3091 year: 2001 end-page: 3102 article-title: Intergroup rhabdomyosarcoma study‐IV: Results for patients with nonmetastatic disease publication-title: J Clin Oncol – volume: 95 start-page: 377 year: 2002 end-page: 388 article-title: Adult rhabdomyosarcoma: Outcome following multimodality treatment publication-title: Cancer – volume: 2 start-page: 19 year: 1979 end-page: 28 article-title: Evaluation of intensified chemotherapy in children with advanced rhabdomyosarcoma (clinical groups III and IV). The Intergroup Rhabdomyosarcoma Study (IRS) committee of the cancer and leukemia group B children's cancer study group, Southwest oncology group publication-title: Cancer Clin Trials – volume: 119 start-page: 656 year: 2013 end-page: 664 article-title: The degree of tumor volume reduction during the early phase of induction chemotherapy is an independent prognostic factor in patients with high‐risk neuroblastoma publication-title: Cancer – volume: 119 start-page: 1578 year: 2013 end-page: 1585 article-title: Radiation therapy target volume reduction in pediatric rhabdomyosarcoma: Implications for patterns of disease recurrence and overall survival publication-title: Cancer – volume: 28 start-page: 67 year: 1989 end-page: 72 article-title: The predictive value of initial cytostatic response in primary unresectable rhabdomyosarcoma in children publication-title: Acta Oncol – volume: 37 year: 2001 article-title: Response rate and prognosis depending on response in rhabdomyosarcoma. A report from the CWS Study publication-title: Pediatr Blood Cancer – volume: 50 start-page: 816 year: 2014 end-page: 823 article-title: Early response as assessed by anatomic imaging does not predict failure‐free survival among patients with group III rhabdomyosarcoma: A report from the Children's Oncology Group publication-title: Eur J Cancer – start-page: 95 year: 2010 end-page: 112 – volume: 366 start-page: 1371 year: 2012 end-page: 1381 article-title: Outcomes after induction failure in childhood acute lymphoblastic leukemia publication-title: N Engl J Med – volume: 20 start-page: 776 year: 2002 end-page: 790 article-title: Prognostic factors in high‐grade osteosarcoma of the extremities or trunk: An analysis of 1, 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols publication-title: J Clin Oncol – volume: 30 start-page: 2431 year: 2012 end-page: 2433 article-title: Playing bad cards properly: Challenges to improving cure rates in rhabdomyosarcoma publication-title: J Clin Oncol – volume: 56 start-page: 718 year: 2011 end-page: 724 article-title: Treatment efficiency, outcome and surgical treatment problems in patients suffering from localized embryonal bladder/prostate rhabdomyosarcoma: A report from the cooperative soft tissue sarcoma trial CWS‐96 publication-title: Pediatr Blood Cancer – volume: 60 start-page: 1574 year: 2013 end-page: 1581 article-title: Effective childhood cancer treatment: The impact of large scale clinical trials in Germany and Austria publication-title: Pediatr Blood Cancer – volume: 67 start-page: 497 year: 2007 end-page: 504 article-title: Spot‐scanning proton therapy for malignant soft tissue tumors in childhood: First experiences at the Paul Scherrer Institute publication-title: Int J Radiat Oncol Biol Phys – volume: 27 start-page: 5182 year: 2009 end-page: 5188 article-title: Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate‐risk rhabdomyosarcoma: Children's oncology group study D 980 publication-title: J Clin Oncol – volume: 355 start-page: 1572 year: 2006 end-page: 1582 article-title: Chronic health conditions in adult survivors of childhood cancer publication-title: N Engl J Med – year: 1926 – volume: 27 start-page: 1446 year: 2009 end-page: 1455 article-title: Cooperative trial CWS‐91 for localized soft tissue sarcoma in children, adolescents, and young adults publication-title: J Clin Oncol – volume: 27 start-page: 3705 year: 2009 end-page: 3711 article-title: Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: A report from the children's oncology group publication-title: J Clin Oncol – volume: 28 start-page: 4228 year: 2010 end-page: 4232 article-title: Early treatment failure in intermediate‐risk rhabdomyosarcoma: results from IRS‐IV and D 9803—a report from the children's oncology group publication-title: J Clin Oncol – volume: 115 start-page: 3206 year: 2010 end-page: 3214 article-title: Molecular response to treatment redefines all prognostic factors in children and adolescents with B‐cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP‐BFM ALL 2000 study publication-title: Blood – ident: e_1_2_6_21_1 doi: 10.1080/01621459.1958.10501452 – ident: e_1_2_6_4_1 doi: 10.1016/S1470-2045(05)01733-X – start-page: 95 volume-title: Cancer in children and adolescents. Volume 1 year: 2010 ident: e_1_2_6_34_1 contributor: fullname: Widemann BC – ident: e_1_2_6_10_1 doi: 10.1200/JCO.2002.20.3.776 – ident: e_1_2_6_17_1 doi: 10.1200/JCO.2006.10.4257 – ident: e_1_2_6_32_1 doi: 10.1200/JCO.2009.22.3768 – ident: e_1_2_6_31_1 doi: 10.1016/j.ejca.2013.11.031 – ident: e_1_2_6_40_1 doi: 10.1016/j.ijrobp.2006.08.053 – ident: e_1_2_6_39_1 doi: 10.1016/j.ejca.2007.01.033 – ident: e_1_2_6_7_1 doi: 10.1182/blood-2009-10-248146 – volume: 2 start-page: 19 year: 1979 ident: e_1_2_6_37_1 article-title: Evaluation of intensified chemotherapy in children with advanced rhabdomyosarcoma (clinical groups III and IV). The Intergroup Rhabdomyosarcoma Study (IRS) committee of the cancer and leukemia group B children's cancer study group, Southwest oncology group publication-title: Cancer Clin Trials contributor: fullname: Raney RB – ident: e_1_2_6_2_1 doi: 10.1016/j.ejca.2007.11.013 – ident: e_1_2_6_25_1 doi: 10.1007/978-1-4419-0284-9_18 – ident: e_1_2_6_43_1 doi: 10.1016/S0360-3016(01)01709-6 – ident: e_1_2_6_30_1 doi: 10.1200/JCO.2010.29.0247 – ident: e_1_2_6_19_1 doi: 10.1007/s00508-004-5-0285-8 – ident: e_1_2_6_8_1 doi: 10.1200/JCO.1999.17.12.3736 – ident: e_1_2_6_11_1 doi: 10.3109/02841868909111184 – volume: 60 start-page: 32 year: 2013 ident: e_1_2_6_20_1 article-title: Report of the CWS‐2002 ‐P study: Treatment results for soft tissue sarcomas (STS) in childhood and adolescence publication-title: Pediatr Blood Cancer contributor: fullname: Koscielniak E – ident: e_1_2_6_5_1 doi: 10.1200/JCO.2007.12.2382 – ident: e_1_2_6_18_1 doi: 10.1200/JCO.2008.19.5933 – ident: e_1_2_6_9_1 doi: 10.1002/cncr.27775 – ident: e_1_2_6_24_1 doi: 10.1056/NEJMoa1110169 – ident: e_1_2_6_33_1 doi: 10.1200/JCO.2012.42.4275 – ident: e_1_2_6_36_1 doi: 10.1200/JCO.2005.11.909 – ident: e_1_2_6_14_1 doi: 10.1002/1097-0142(19921115)70:10<2557::AID-CNCR2820701027>3.0.CO;2-8 – ident: e_1_2_6_3_1 doi: 10.1056/NEJMsa060185 – ident: e_1_2_6_12_1 doi: 10.1016/S0959-8049(98)00024-0 – ident: e_1_2_6_23_1 doi: 10.1002/(SICI)1097-0142(19971101)80:9<1717::AID-CNCR4>3.0.CO;2-B – ident: e_1_2_6_15_1 doi: 10.1200/JCO.2007.15.0466 – ident: e_1_2_6_26_1 doi: 10.1002/pbc.24598 – ident: e_1_2_6_38_1 doi: 10.1002/pbc.22950 – ident: e_1_2_6_29_1 doi: 10.1002/cncr.10669 – volume: 37 year: 2001 ident: e_1_2_6_42_1 article-title: Response rate and prognosis depending on response in rhabdomyosarcoma. A report from the CWS Study publication-title: Pediatr Blood Cancer contributor: fullname: Mattke A – ident: e_1_2_6_13_1 doi: 10.1200/JCO.1999.17.12.3706 – ident: e_1_2_6_27_1 doi: 10.1200/JCO.1988.6.2.308 – volume-title: Reports on public health and medical subjects the errors of sampling of the survivorship tables year: 1926 ident: e_1_2_6_22_1 contributor: fullname: Greenwood M – ident: e_1_2_6_35_1 doi: 10.1002/1097-0142(197412)34:6<2128::AID-CNCR2820340638>3.0.CO;2-M – ident: e_1_2_6_28_1 doi: 10.1200/JCO.2009.25.0803 – ident: e_1_2_6_16_1 doi: 10.1200/JCO.2001.19.12.3091 – ident: e_1_2_6_6_1 doi: 10.1001/jama.290.12.1583 – ident: e_1_2_6_41_1 doi: 10.1002/cncr.27934 |
| SSID | ssj0026058 |
| Score | 2.282443 |
| Snippet | Background
Response (tumour volume reduction) to induction chemotherapy has been used to stratify secondary local and systemic treatment of Intergroup... Response (tumour volume reduction) to induction chemotherapy has been used to stratify secondary local and systemic treatment of Intergroup Rhabdomyosarcoma... Background Response (tumour volume reduction) to induction chemotherapy has been used to stratify secondary local and systemic treatment of Intergroup... BACKGROUNDResponse (tumour volume reduction) to induction chemotherapy has been used to stratify secondary local and systemic treatment of Intergroup... BACKGROUND: Response (tumour volume reduction) to induction chemotherapy has been used to stratify secondary local and systemic treatment of Intergroup... |
| SourceID | swepub proquest crossref pubmed wiley istex |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 16 |
| SubjectTerms | Adolescent Adult Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chemotherapy Child Child, Preschool embryonal rhabdomyosarcoma Female Follow-Up Studies Hematology Humans Infant Infant, Newborn Lymphatic Metastasis Male Multivariate analysis Neoadjuvant Therapy Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Neoplasm Staging Oncology Ovarian cancer Pediatrics Prognosis response Retrospective Studies Rhabdomyosarcoma, Embryonal - drug therapy Rhabdomyosarcoma, Embryonal - mortality Rhabdomyosarcoma, Embryonal - pathology Survival Rate Tumor Burden Young Adult |
| Title | Tumour volume reduction after neoadjuvant chemotherapy impacts outcome in localised embryonal rhabdomyosarcoma |
| URI | https://api.istex.fr/ark:/67375/WNG-HXQXW9VQ-8/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpbc.25207 https://www.ncbi.nlm.nih.gov/pubmed/25263634 https://www.proquest.com/docview/1625612459 https://search.proquest.com/docview/1627070767 https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-240257 |
| Volume | 62 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagSIgL5U2gRQYB4pI2sZ2HxalP9kLVitLuzbJjGxaUpEo2UvffM7azQZVAQuIWyZPEmYdnxpP5jNBbyg1RhU5ixUsVM86SWFrD4sQWMnWIVcZv5sy-FCfz8vDIweR8XPfCBHyIacPNWYZfr52BS9Xv_gYNvVLVDsmI7ySHLMG3b9DTKdly5T6PlcqyOINAYo0qlJDd6c4bvuiOY-v1nwLNCUX0ZgDrPdDx5n_N_QG6PwaeeC9oykN0yzSP0N3PY2n9MWrOhxpocFiucOcgXZ3QsD9FHDemlfrHAHH3EoOc67Fxa4VDm2WP22EJszB40WDvHxe90djUqlu5WB9336XSbb1qe7CstpZP0Nfjo_ODWTwexhBXLquKq8RCNKNKzZixmtGK5SUpKmVtzqqEMlvk4PeIzaQqEptpWlnLOckNSFvmMqVP0UbTNuY5whVNZUKMhFxOM6s5t0yxVCcOy5BYTSP0Zi0WcRUwN0RAVyYCOCc85yL03gtsopDdT_eTWpGJy5NPYjY_m1_yizNRRmhrLVEx2mcvUkj7QBNZxiP0ehoGy3LlEgksHTxN4cCQcnjXs6AJ08tgCjnNKYvQu6Aa04iD6z5cXOyJtvsmhkG46lUGT_jg9eHv3yNO9w_8xYt_J32J7kH8loUdoS20sewGs41u93p45Y3hFzX2DEg |
| link.rule.ids | 230,315,782,786,887,1408,4030,27934,27935,27936,46066,46490 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9QwELaglYAX7iNQwCBAvIQmtnNY4qX0YBHtqhXbdt8sO7ZhQUmqZCOx_56xkw2qBBISb5E8SZw5POOZzGeEXlFuiMp0FCqeq5BxFoXSGhZGNpOxQ6wyPpkz-ZJN5_nevoPJeb_uhenxIcaEm7MMv147A3cJ6e3fqKEXqnhHEuJayTdZyrg7uIHS43G75Qp-Hi2VJWECocQaVygi2-Otl7zRpmPszz-FmiOO6OUQ1vugg1v_N_vb6OYQe-KdXlnuoCumuouuHQ3V9XuomnUl0OB-xcKNQ3V1csP-IHFcmVrq7x2E3ksMoi6H3q0V7jstW1x3S5iGwYsKexe5aI3GplTNyoX7uPkmla7LVd2CcdWlvI9OD_Znu5NwOI8hLNzGKiwiCwGNyjVjxmpGC5bmJCuUtSkrIspsloLrIzaRKotsomlhLeckNSBwmcqYPkAbVV2ZRwgXNJYRMRK2c5pZzbllisU6cnCGxGoaoJdruYiLHnZD9ADLRADnhOdcgN54iY0Usvnh_lPLEnE-_Sgm85P5OT87EXmAttYiFYOJtiKGnR8oI0t4gF6Mw2BcrmIigaWdp8kcHlIK73rYq8L4MphCSlPKAvS6141xxCF27y3OdkTdfBVdJ1wBK4EnvPUK8ffvEccfdv3F438nfY6uT2ZHh-Lw0_TzE3QDwrmkTxBtoY1l05mn6Gqru2feMn4B_sMQaQ |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaglSouvB8pLRgEiEvaxHZe4tR2uywCVltR2r1ZdmzDUiVZJRuJ_fd4nGxQJZCQuEXyJHE8M55v7MxnhF7RTBOZqMCXWSp9lrHAF0YzPzCJCIGxSrvFnMmXZDpPR6dAk_NuUwvT8UMMC27gGW6-BgdfKnP4mzR0KfMDEhGoJN9mAMOhfoPOhmwL9vscWSqL_MgiiQ2tUEAOh1uvBaNtGNeff0KaA43odQTrQtD4zn91_i663SNPfNSZyj10Q5f30c7nfm_9ASrP28LK4G6-wjVwuoLWsDtGHJe6EupHa4H3CltFF33l1hp3dZYNrtqV7YXGixK7ALlotMK6kPUawD6uvwupqmJdNda1qkI8RF_Hp-cnE78_jcHPIa3y88BYOCNTxZg2itGcxSlJcmlMzPKAMpPENvAREwmZBCZSNDcmy0isrbpFLEL6CG2VVamfIJzTUAREC5vMKWZUlhkmWagCIDMkRlEPvdyohS870g3e0SsTbkeOu5Hz0BunsEFC1Ffwl1oS8cvpez6Zn80vs4sznnpob6NR3jtow0Ob91lTZFHmoRdDs3Ut2C8RdkhbJ5MAG1Js3_W4s4ThZbYLMY0p89DrzjSGFuDrHi0ujnhVf-Nty2H7KrJPeOvs4e_fw2fHJ-5i999Fn6Od2WjMP32YfnyKblksF3WrQ3toa1W3eh_dbFT7zPnFL8Q0Dxg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tumour+volume+reduction+after+neoadjuvant+chemotherapy+impacts+outcome+in+localised+embryonal+rhabdomyosarcoma&rft.jtitle=Pediatric+blood+%26+cancer&rft.au=Dantonello%2C+Tobias+M&rft.au=Stark%2C+Monika&rft.au=Timmermann%2C+Beate&rft.au=Fuchs%2C+J%C3%B6rg&rft.date=2015&rft.issn=1545-5009&rft.volume=62&rft.issue=1&rft.spage=16&rft_id=info:doi/10.1002%2Fpbc.25207&rft.externalDocID=oai_DiVA_org_uu_240257 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1545-5009&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1545-5009&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1545-5009&client=summon |